PARp for gliomas – pro
PARP use in gliomas is based on the presence of BRCA mutation in this cancer. They are not active without BRCA mutations. Among various strategies of inducing death in cancer cells, inhibition of poly(ADP-ribose) polymerase (PARP) has emerged as a beneficial therapy when combined with other anticancer agents. There are a few publications recently, mostly exploring the further study of PARP inhibitors and a few small series. It is not recommended by any guidelines.
S. Lai et al, A therapeutic update on PARP inhibitors: implications in the treatment of glioma. Drug Discovery Today Volume 26, Issue 2, February 2021, Pages 532-541
Sim, H.-W.; Galanis, E.; Khasraw, M. PARP Inhibitors in Glioma: A Review of Therapeutic
Opportunities. Cancers 2022, 14, 1003.